Discussion of “A hybrid phase I‐II/III clinical trial design allowing dose re‐optimization in phase III” by Andrew G. Chapple and Peter F. Thall-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Discussion of “A hybrid phase I‐II/III clinical trial design allowing dose re‐optimization in phase III” by Andrew G. Chapple and Peter F. Thall

Published:2019-04-03 Issue:2 Volume:75 Page:385-388
ISSN:0006-341X
Container-title:Biometrics
language:en
Short-container-title:Biom

Author:

Zhou Tianjian¹,Ji Yuan¹²

Affiliation:

1. Research InstituteNorthShore University HealthSystem Evanston, Illinois

2. Department of Public Health SciencesThe University of Chicago Chicago, Illinois

Publisher

Wiley

Subject

Applied Mathematics,General Agricultural and Biological Sciences,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine,Statistics and Probability

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/biom.12992

Reference5 articles.

1. Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III

2. Dose-Finding Based on Efficacy-Toxicity Trade-Offs

3. Specifying the true‐and false‐positive rates in basket trials;Cunanan K. M;JCO Precis Oncol,2017

4. Do cancer drugs improve survival or quality of life?

5. A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP